Summary & Overview
HCPCS M0248: Intravenous Sotrovimab Infusion, Home Administration
HCPCS Level II code M0248 represents the intravenous infusion of sotrovimab with included post-administration monitoring when provided in a beneficiary's home or residence. The code covers home-based therapeutic monoclonal antibody administration and explicitly encompasses homes designated as provider-based to a hospital during the COVID-19 public health emergency. This national-level billing descriptor matters because it defines a route for delivering outpatient monoclonal antibody treatment outside traditional infusion centers, with implications for access, coding compliance, and payment policy across payers.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage context, typical site-of-service considerations, and the types of benchmarks and policy updates commonly reviewed for HCPCS Level II infusion codes. The publication outlines billing and service-line implications for home infusion of sotrovimab, notes relevant clinical context for monoclonal antibody therapy, and flags where data is not available in the input. This summary serves clinicians, billing professionals, and policy analysts seeking a clear, national-level briefing on HCPCS Level II code M0248.
Billing Code Overview
HCPCS Level II code M0248 describes intravenous infusion of sotrovimab, including the infusion procedure and post-administration monitoring provided in the beneficiary's home or residence. The description explicitly includes care delivered to a beneficiary's home that was made provider-based to the hospital during the COVID-19 public health emergency.
-
Service type: Therapeutic monoclonal antibody infusion administered intravenously in the home setting
-
Typical site of service: Patient's home or residence (including homes designated as provider-based to a hospital during the COVID-19 public health emergency)
Clinical & Coding Specifications
Clinical Context
A 68-year-old community-dwelling patient with multiple comorbidities (type 2 diabetes, chronic kidney disease stage 3, and congestive heart failure) tests positive for SARS-CoV-2 and is assessed in an outpatient infusion-at-home program. The patient meets clinical criteria for monoclonal antibody therapy and is scheduled for administration of sotrovimab via intravenous infusion at the patient’s residence. A licensed infusion nurse and an advanced practice clinician perform a pre-infusion assessment, verify informed consent, review medication reconciliation, establish IV access, and prepare sotrovimab using an approved protocol. The infusion nurse administers the medication, monitors vital signs and oxygen saturation during infusion, and provides post-administration observation per manufacturer and emergency preparedness guidelines. Documentation includes time of infusion start and stop, lot number, dose, patient tolerance, and any adverse events. If a serious infusion reaction occurs, the team documents interventions and arranges emergency transport. Billing uses HCPCS Level II code M0248 to capture the infusion and post-administration monitoring in the home or provider-based residence under the public health emergency provisions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to provide the infusion is substantially greater than typical (detailed documentation required). |